Skip to main content
Premium Trial:

Request an Annual Quote

Pairings: Mar 16, 2011


Agendia has made three appointments to its executive team. David Macdonald has been named chief operating officer, Mark Willig is executive vice president of North American sales, and Doug Bradley has been appointed vice president of global marketing.

Macdonald has been involved in commercializing clinical diagnostics and lab services tools at Nanogen, AltheaDx, Behring Diagnostics, and the Nichols Institute. Willig was general manager and chief commercial officer at Exiqon, vice president of global sales for Thermo Fisher's pathology business, and worked at Myriad Genetics and Abbott Diagnostics. Bradley has worked at Coherent Medical, Allergan, SenoRx, and at Vertos Medical.

John Krayacich has joined Exact Sciences as senior vice president of sales and marketing.

Krayacich was most recently president and chief executive officer of two startup biotechnology companies: Ambrose Pharmaceuticals and Marinus Pharmaceuticals. Prior to that, Krayacich held executive positions at Novartis, Pfizer Neurosciences, and Parke-Davis.

Jay Moyes has been appointed to the board of directors at Integrated Diagnostics. Moyes was previously chief financial officer of Myriad Genetics and chief financial officer of XDx. He is currently director and chair of the audit committees of both Osiris Therapeutics and BioCardia.

Filed under

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.